This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary to get the Daily Monster Market Commentary and join the 2,935 subscribers getting it for FREE!
Amazon Is Just Having Fun
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Subscribe
Is Amazon just screwing with Wall Street analyst or what? Last quarter the e-commerce giant missed analyst EPS estimates by nearly 72 percent. This quarter the company reported diluted EPS of $0.52, beating analyst estimates for a loss of $0.01.
When looking and comparing the result from the second quarter to the third quarter, it is striking because Amazon reported income before taxes of $316 million, while in the second quarter the company reported income before taxes of $666 million.
The only reason why Amazon results on EPS were so much stronger than estimates was because Amazon only paid 58 million in taxes for the third quarter, versus $467 million in the second. Amazon would have had a loss in the quarter. The tax saving allowed Amazon to have net income of $256 million.
It wasn’t because Amazon suddenly decided to spend less because R&D and Marketing remained pretty much unchanged for the third quarter versus the second quarter.
As for the fourth quarter, analysts will now be forced to raise all those estimates again, only for Amazon to do something unexpected in the fourth quarter. The analyst shouldn’t even bother trying to figure it out.
Subscribe to the MCM Stock Market Commentary to get it Daily and join the 2,935 subscribers getting it for FREE!
There were so many earning today that we can’t go through all of them, but one that clients of Mott own, and I’m still trying to understand better is Celgene. The stock got crushed last week, on the discontinuation of trials for its Drug GED-0301. So rightfully, Celgene updated guidance for the long-term, for the year 2020 to be exact. They lowered revenue estimate to a $19.5 billion at the mid-point, from $21 billion, and took EPS guidance down to $12.50 per share, from $13.00.
The stock tanked today. On October 4, the stock was trading at about $147; it closed at $99.99 on October 26. The first wave of selling came after the announcement of the trial discontinuation, on October 5. The second wave happened today when the stock fell again. If Celgene does earn $12.50 in 2020, it would mean the stock is trading at less than ten times 2020 earnings and about four times future sales.
I was reading in place, some of the weakness in the stock was due to the Otzela, with revenue for the coming in about $100 million less than estimates, at roughly $300 million. To put it in perspective the company reported revenue in the quarter of $3.2 billion. Otzela missed by $100 million, sounds like a rounding error in all seriousness.
Here’s the other thing, the company lowered total guidance by about $1.5 billion or 7 percent.
We can slice and dice things however one wants, but here is a stock trading at $147 just two weeks sitting at $100 now, a decline of 32 percent. For a 7 percent reduction in revenue for the year 2020, which will likely be adjusted a few times over the course of the next few years.
Apparently, the market has decided that Celgene should now be valued on par with Gilead. A company that has declining revenue and has declining EPS.
Something to think about.
Watch my interview on Cheddar! Talking Qualcomm/NXPI
Qualcomm is still battling to secure its acquisition of Dutch chipmaker NXP Semiconductors. The tender offer expires on November 17th, but with the stock trading above the $110 offer price, will the deal get done? Seeking Alpha author Michael Kramer says it won’t close at that price.
Free Articles From Mike:
We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]
Michael Kramer and the clients of Mott Capital own shares of CELG
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.